To develop an evidence and consensus-based radiosurgery practice guideline for brain metastases treatment, recommendations to be used by medical and public health professionals who diagnose and manage patients with brain metastatic disease, and to improve outcomes for brain metastases radiosurgery by assisting physicians and clinicians in applying research evidence to clinical decisions while promoting the responsible use of health care resources.

Target Population

Patients diagnosed with metastatic brain disease

Interventions and Practices Considered

1. Pre-radiosurgery evaluation including high resolution double dose contrast-enhanced magnetic resonance imaging (MRI) (or computed tomography [CT])
2. Stereotactic radiosurgery (SRS) (alone or as a boost after whole-brain radiation therapy [WBRT]) using Gamma Knife, proton beam, or dedicated linear accelerators
3. Corticosteroids (a single stress dose) at the conclusion of radiosurgery procedure
4. Chemotherapy
5. Other medications (e.g., anticonvulsants, antiedema drugs)
6. Follow up including MRI scans at specific intervals
7. Surgical decompression for patients with large tumors causing symptomatic mass effect

Major Outcomes Considered
- Tumor growth control
- Overall survival
- Recurrence rate
- Functional improvement
- Adverse events
- Quality of life
- Overall patient satisfaction

Methodology

Methods Used to Collect/Select the Evidence
- Hand-searches of Published Literature (Primary Sources)
- Hand-searches of Published Literature (Secondary Sources)
- Searches of Electronic Databases

Description of Methods Used to Collect/Select the Evidence
MEDLINE and PUBMED searches were completed for the years 1966 to May 2008. Search terms included: brain metastases, metastatic brain tumor, stereotactic radiosurgery, Gamma Knife®, linear accelerator, irradiation, clinical trials, research design, practice guidelines and meta-analysis. Bibliographies from recent published reviews were reviewed and relevant articles were retrieved.

Number of Source Documents
Not stated

Methods Used to Assess the Quality and Strength of the Evidence
- Expert Consensus (Committee)
- Weighting According to a Rating Scheme (Scheme Given)

Rating Scheme for the Strength of the Evidence
This classification is based on the Bandolier system (http://www.medicine.ox.ac.uk/bandolier/band6/b6-5.html) adapted for a systematic review.

Type & Strength of Evidence in Medical Literature
- **Type I**: Evidence from a systematic review (which includes at least one randomized controlled trial and a summary of all included studies).
- **Type II**: Evidence from a well designed randomized controlled trial of appropriate size.
- **Type III**: Evidence from a well designed intervention study without randomization. A common research design is the before-and-after study.
- **Type IV**: Evidence from a well designed non-experimental study, e.g., cohort, case-control or cross-sectional studies. (Also includes studies using purely qualitative methods. Economic analyses [cost-effectiveness studies] are also classified as Type IV evidence.)
- **Type V**: Opinions of respected authorities, based on clinical evidence, descriptive studies or reports of expert consensus committees.

Methods Used to Analyze the Evidence
- Review of Published Meta-Analyses
- Systematic Review with Evidence Tables

Description of the Methods Used to Analyze the Evidence
The literature identified was reviewed and opinions were sought from experts in the diagnosis and management of brain metastases including members of the working group.

Methods Used to Formulate the Recommendations
- Expert Consensus
Description of Methods Used to Formulate the Recommendations

The working group included physicians and physicists from the staff of major medical centers that provide radiosurgery. The initial draft of the consensus statement was a synthesis of research information obtained in the evidence gathering process.

Members of the working group provided formal written comments that were incorporated into the preliminary draft of the statement. No significant disagreements existed.

The final statement incorporates all relevant evidence obtained by the literature search in conjunction with the final consensus recommendations supported by all working group members listed in the original guideline document.

Rating Scheme for the Strength of the Recommendations

Not applicable

Cost Analysis

Guideline developers reviewed published cost analyses.

Method of Guideline Validation

External Peer Review
Internal Peer Review

Description of Method of Guideline Validation

The recommendations were e-mailed to all committee members. Feedback was obtained through this e-mail survey consisting of proposed guidelines asking for comments on the guidelines and whether the recommendation should serve as a practice guideline. No significant disagreements existed.

This practice guideline, together with a report on "Metastatic Brain Tumor Management" is an original guideline approved by the International RadioSurgery Association and issued in May 2008.

Recommendations

Major Recommendations

- Patients with brain metastases, defined by modern neurodiagnostic imaging (computed tomography [CT], magnetic resonance imaging [MRI] scan) constitute the study group. Such patients typically present with seizures or symptoms of mass effects such as headache, nausea, vomiting, weakness, numbness of limbs or speech problems. Many patients’ tumors are detected due to MRI surveillance before they develop any symptoms.
- Stereotactic radiosurgery is a minimally invasive, single session, high-dose, closed skull strategy that may be especially suitable for patients who have limited metastatic brain disease and have controlled systemic disease with good functional status.
- Stereotactic radiosurgery is typically employed alone or as a boost after whole-brain radiation therapy (WBRT) for patients with metastatic brain tumors.
- A high resolution double dose contrast-enhanced MRI is usually necessary to determine the number of metastatic tumors. For radiosurgery dose planning, double dose contrast-enhanced volumetric gradient recalled recalled MR stereotactic images are ideal.
- Current radiation delivery technologies for volumetric stereotactic conformal single session radiosurgery include Gamma Knife®, proton beam using Bragg peak effect, and specially modified or dedicated linear accelerators like Novalis® and Axesse®.
- The optimal dose range for volumetric conformal stereotactic brain metastases radiosurgery has been largely established based on tumor anatomy (proximity to eloquent brain regions), tumor volume, prior radiation therapy and estimated adverse radiation risks. Minimum doses to the margin typically range from 14 to 24 Gy in a single session.
- Patients may receive a single stress dose of corticosteroids at the conclusion of the radiosurgery procedure. Patients can continue to take other medications (antiseizure or antiedema drugs) as recommended by their physicians.
- Post-radiosurgical clinical examinations and MRI studies are requested by referring physicians at 2 to 3 month intervals or earlier if the patient develops a new symptom suggestive of a new tumor, brain edema or hemorrhage.
- Patients with large tumors causing symptomatic mass effect may need surgical decompression of the tumor. Residual tumor or tumor bed can be treated by radiosurgery or radiation therapy.
- Causes for local failure of stereotactic radiosurgery include inadequate visualization of the tumor, lack of intraoperative stereotactic three-dimensional (3-D) (volumetric) imaging, new metastatic deposits and insufficient dose (due to large tumor volume and proximity to eloquent brain locations) to achieve the growth control response.

Clinical Algorithm(s)

Algorithms are provided in the original guideline document for:

- Brain Lesion Suggestive of Metastasis on Magnetic Resonance Imaging (MRI)
- Single Brain Metastasis on MRI
- Limited (2–4) Brain Metastases on MRI
Evidence Supporting the Recommendations

Type of Evidence Supporting the Recommendations

Type I, II, and III evidence exists in support of stereotactic radiosurgery for brain metastases. Refer to the "Rating Scheme for the Strength of the Evidence" field.

Benefits/Harms of Implementing the Guideline Recommendations

Potential Benefits

Overall Benefits
Improved management of patients with brain metastases

Specific Benefits
Benefits of radiosurgery include minimally invasive approach and high rates of tumor growth control (80 to 90%).

Subgroup(S) Most Likely to Benefit
- Patients diagnosed with small to medium size brain metastases without symptomatic brain compression.
- Patients with residual or recurrent brain metastases after resection.
- Patients with residual or recurrent brain metastases after whole-brain radiotherapy (WBRT).

Potential Harms
- Major adverse effects of radiosurgery are based on location, volume, and dose, and these risks can be estimated based on published data and experience. Individual risks are related to the anatomic location of tumors.
- The overall side effects of stereotactic radiosurgery (SRS) are limited but can occasionally be serious. There are very few acute side effects of SRS related to the radiation. Stereotactic radiosurgery may cause mild fatigue and sometimes a temporary patch of hair loss if the tumor is close to the skull and scalp. There is a risk of late side effects that can develop, the most common and serious of which is tumor radionecrosis. Radiation necrosis is damage to the tumor and/or adjacent brain in the high-dose area. This can result in edema and additional side effects produced by the mass including seizures and neurological deficits. Radionecrosis can often be managed with corticosteroids. Occasionally surgical intervention is required to reduce the mass effect. The risk of symptomatic radionecrosis is usually less than 5%.

Subgroup(s) Likely to Be Harmed
Patients with large volume tumors causing symptomatic mass effect on the brain.

Contraindications

Contraindications
Brain metastasis diameter greater than 4 cm is a relative contraindication dependent upon individual circumstance.

Qualifying Statements

Qualifying Statements
- This guideline is intended to provide the scientific foundation and initial framework for the person who has been diagnosed with a vestibular schwannoma. The assessment and recommendations provided in this guideline represent the best professional judgment of the working group at this time, based on research data and expertise currently available. The conclusions and recommendations will be regularly reassessed as new information becomes available.
- This guideline is not intended as a substitute for professional medical advice and does not address specific procedures or conditions for any patient. Those consulting this guideline are to seek qualified consultation utilizing information specific to their medical situation. Further, International RadioSurgery Association (IRSA) does not warrant any instrument or equipment nor make any representations concerning its fitness for use in any particular instance nor any other warranties whatsoever.

Implementation of the Guideline

Description of Implementation Strategy
An implementation strategy was not provided.

Implementation Tools
Clinical Algorithm

Patient Resources
For information about availability, see the Availability of Companion Documents and Patient Resources fields below.
To develop an evidence and consensus statement, the overall side effects of stereotactic radiosurgery (SRS) are limited but can occasionally be serious. There are limited data available for high-dose stereotactic radiosurgery (SRS) and hypofractionated stereotactic radiotherapy (SRT) for patients with metastatic brain tumors. SRS and SRT can be performed in patients with a broad range of primary tumors, regardless of their neutron status. The recurrence rate for brain metastases is relatively low, and the major adverse effects of radiosurgery are based on location, volume, and dose, and these risks can be estimated with a high degree of accuracy. A high resolution double dose contrast magnetic resonance imaging (MRI) scan (or computed tomography [CT]) of the brain is the most important factor in determining the potential impact of radiosurgery on patients with large volume tumors. Patients diagnosed with metastatic brain disease should be evaluated by a neurosurgeon and an oncologist. The assessment and recommendations provided in this guideline represent the best professional judgment of the working group at this time, based on research data and expertise currently available. Novalis Tx™ and Axesse™images are ideal. Many patients' tumors are detected due to MRI surveillance before they develop any symptoms. Follow up including MRI scans at specific intervals or earlier if the patient develops a new symptom suggestive of a new tumor, brain edema or hemorrhage. Patients can continue to take other medications (antiseizure or antiedema drugs) as recommended by their primary care provider. The clinical specialty groups represented on the Guideline Development Committee included: Neurosurgeons, Radiation Oncologists, Medical Oncologists, Neuro-oncologists, Radiation Oncology, Oncology, Advanced Practice Nurses, and Physicists. Community representatives did not participate in the development of this guideline. The initial draft of the consensus statement was a synthesis of research information obtained in the evidence development process. The research evidence for this guideline was classified into major outcomes considered, target population, methods used to collect/select the evidence, methods used to analyze the evidence, methods used to formulate the recommendations, and qualitative assessment. Type I, II, and III evidence exists in support of stereotactic radiosurgery for brain metastases. Refer to the "Rating the Evidence" field. Type V evidence is also included. Qualifying Statements. The guideline was developed by the International RadioSurgery Association. The majority of the authors were radiation oncologists and neurosurgeons, and some were medical oncologists and physicists. Community representatives did not participate in the development of this guideline. The IRSA Medical Advisory Board Guidelines Committee and representatives in the industry. IRSA makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of a personal, professional, or business interest of a member of the radiosurgery guidelines group. This is the current release of the guideline. Electronic copies: Available Portable Document Format (PDF) from the IRSA Web site. Print copies: Available from the IRSA (International RadioSurgery Association), 3002 N. 2nd Street, Harrisburg, PA 17110. None available. The following is available:

Patients with residual or recurrent brain metastases after resection. This guideline is intended to provide the scientific foundation and initial framework for the person who has been determined that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion-criteria.aspx.

NGC Status
This NGC summary was completed by ECRI Institute on August 22, 2008. The information was verified by the guideline developer on September 23, 2008.

Copyright Statement
This guideline is copyrighted by IRSA (International RadioSurgery Association) and may not be reproduced without the written permission of IRSA. IRSA reserves the right to revoke copyright authorization at any time without reason.

Disclaimer
NGC Disclaimer
The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion-criteria.aspx.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.